Steven St. Peter

Steven St. Peter, M.D. joined the T1D Fund in 2019, following a seven-year career at Aratana Therapeutics (NASDAQ: PETX), where he served as a Founder, President, and Chief Executive Officer. Previously, as a Managing Director at MPM Capital, and through positions at Apax Partners and The Carlyle Group, Dr. St. Peter has founded, invested in, and/or been involved with several life sciences companies including Align Technologies (NASDAQ: ALGN), Medpointe, ESP Pharma, SkinMedica, Omrix (NASDAQ: OMRI), Pharmathene (NYSE: PIP), Xanodyne, Syndax (NASDAQ: SNDX), EKR Therapeutics, Proteon (NASDAQ: PRTO), Rhythm (NASDAQ: RYTM). Dr. St. Peter has served on the Executive Committee & Board of Directors of the New England Venture Capital Association. Dr. St. Peter holds an M.D. from Washington University, an M.B.A. in Finance from the Wharton School of the University of Pennsylvania, and a B.A. in Chemistry from the University of Kansas, and had held the position of Assistant Clinical Professor of Medicine at Columbia University.